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Abstract
Background: Breast cancer patients under neoadjuvant chemotherapy includes a heterogeneous group of patients
who eventually develop distal disease, not detectable by current methods. We propose the use of exosomal
miRNAs and circulating tumor cells as diagnostic and predictive biomarkers in these patients.
Methods: Fifty-three breast cancer women initially diagnosed with localized breast cancer under neoadjuvant
chemotherapy were prospectively enrolled in this study. However, six of them were later re-evaluated and
diagnosed as metastatic breast cancer patients by PET-CT scan. Additionally, eight healthy donors were included.
Circulating tumor cells and serum exosomal miRNAs were isolated from blood samples before and at the middle of
neoadjuvant therapy and exosomal miRNA levels analyzed by qPCR.
Results: Before neoadjuvant therapy, exosomal miRNA-21 and 105 expression levels were higher in metastatic
versus non-metastatic patients and healthy donors. Likewise, higher levels of miRNA-222 were observed in basal-like
(p = 0.037) and in luminal B versus luminal A (p = 0.0145) tumor subtypes. Exosomal miRNA-222 levels correlated
with clinical and pathological variables such as progesterone receptor status (p = 0.017) and Ki67 (p = 0.05). During
neoadjuvant treatment, exosomal miRNA-21 expression levels directly correlated with tumor size (p = 0.039) and
inversely with Ki67 expression (p = 0.031). Finally, higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155
were significantly associated with the presence of circulating tumor cells.
Conclusion: Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementary
clinical tool for improving breast cancer diagnosis and prognosis.
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Background
Breast cancer (BC) is the most frequently diagnosed can-
cer in women and the second most common cancer
worldwide [1]. Despite considerable advances in early
detection, diagnosis, and treatment, BC is among the
leading causes of cancer-related deaths in women due to
recurrent metastatic disease [2]. Approximately 20 to
25% of women diagnosed with localized BC (LBC) are
subjected to neoadjuvant therapy [3]. These tumors re-
main a noteworthy clinical problem, as a significative
percentage of these patients will develop metastatic dis-
ease, despite appropriate treatment [4, 5]. Therefore,
early detection of the systemic disease is especially im-
portant for improving the clinical outcomes in these pa-
tients [6]. Thus, despite the improvement of the imaging
techniques and diagnostic biomarkers, they are not yet
fully satisfactory, principally due to important limitations
in detecting distal disease [7, 8]. In this context, liquid
biopsy (LB) emerges as an increasing important tool for
early tumor diagnosis, recurrence monitoring, and thera-
peutic guidance [9]. LB provides a non-invasive alterna-
tive to traditional “solid biopsies,” which cannot be
consistently performed in certain situations, in “real
time,” or as easily under recurring sampling and moni-
toring. LB also has significant value improving our
knowledge about the metastatic processes occurring in
blood. Consequently, with further clinical validation, LB
could allow a better patient risk stratification and, there-
fore, a better patient treatment choice [10].
The presence of circulating tumor cells (CTCs) and
cell-free nucleic acids (cfNAs) such as DNA, mRNA,
and microRNA in blood has been recognized, and their
clinical relevance is considered attractive as novel bio-
markers [11, 12].
CTCs can be used as markers of disease progression,
as early indicators of metastasis, and as mediators of
drug resistance in BC [13, 14].
The interest of exosomal microRNAs (EmiRs) in
cancer has been vastly intensified [15]. In fact, aber-
rantly expressed microRNAs in tissues, serum/plasma,
and CTCs have been explored in the development of
new BC biomarkers [16–18]. However, this has not
yet been proved to be successful, mainly due to con-
founding factors impacting levels of circulating miR-
NAs and potentially compromising their potential as
disease biomarkers [19]. In response to this, exosomes
are suggested, as containers of miRNAs, to solve
these problems [20].
In this work, we sought to evaluate the role of an
EmiR panel in the diagnosis and prediction of treatment
response in BC patients under neoadjuvant therapy. We
further correlated the CTC findings with specific EmiR
profiles and clinical and pathological characteristics of
the matching primary tumors.
Methods
Experimental design
BC women (n = 53) initially diagnosed with LBC sus-
ceptible to receive neoadjuvant chemotherapy were
prospectively enrolled in this study. Forty-seven of
them underwent neoadjuvant treatment while the
other six, initially diagnosed as LBC, were newly eval-
uated and considered as metastatic breast cancer
(MBC) after PET-CT scan evaluation (Additional file 1).
Peripheral blood samples (10 ml in EDTA Vacutainer®
tubes for CTCs and 5 ml in BD Vacutainer® SST™ II
Advance tubes for serum) were extracted at diagnosis
time (Ext1) and after 4 cycles of doxorubicin/cyclo-
phosphamide (Ext2). CTCs and exosomes were iso-
lated following the protocol established by our group
[10], and identification and counting were performed
in a computerized fluorescence microscope (Zeiss
AXIO Imager) (Additional file 1).
Biomarker analysis
miRNAs were extracted from exosomes using the Max-
well® 16 miRNA Tissue kit (Promega, USA). Complemen-
tary DNA was synthesized using 10 ng of total miRNA
and the TaqMan™ Advanced miRNA cDNA Synthesis Kit
(Applied Biosystems, USA) following the manufacturer’s
protocol. A panel of five miRNAs was designed based on
their association with previously reported regulatory roles
in cell proliferation, dissemination, and invasion when
overexpressed in BC. In addition, the selection was based
on their reported mRNA targets of genes as ESR1, proges-
terone receptors (PGR), and ERBB2 and oncogenes as
FOXO3, using the database starBase v3.0 [21]: miR21-5p
(significantly correlated with advanced clinical stage,
lymph node metastasis, and poor prognosis) [22],
miR222-3p (facilitates growth, metastasis, and invasion of
a variety of malignant tumors), miR221-3p (predicting dis-
tant metastases and poor prognosis) [23], miR155-5p
(closely related to the status of estrogen receptor (ER) and
PGR) [24], and miR105-5p (potently inducing migration
and proliferation in metastatic breast cancer (MBC) cells)
[25]. Expression levels of miRNAs were analyzed using
TaqMan™ MicroRNA assay probes and TaqMan™ Univer-
sal PCR Master Mix (Applied Biosystems, USA) in a
7900HT Fast Real-Time PCR System.
Statistical methods
The main objective was to investigate the expression of
five microRNAs in exosomes of BC patients and correl-
ate their expression levels with clinical and pathological
parameters and BC subtypes. The secondary objective
was to test the association between the presence of CTC
count at baseline and EmiR expression.
The statistical analyses were performed using R and
SPSS 14.0 software (SPSS). To test if the microRNA
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expression was significantly different between patients
with different clinicopathological parameters and BC
subtypes, a non-parametric Wilcoxon signed-rank test
was used when two groups were compared. To com-
pare more than two groups, a non-parametric
Kruskal-Wallis test was used instead. To test the cor-
relation between number of CTCs and expression of
EmiRs, Spearman’s rank correlation coefficient was
used. Logistic binary regression and receiver-operating
characteristics (ROC) curves were performed to test
the sensibility and specificity of the Emir-21 (Ext1)
and clinical biomarkers to identify MBC.
The presence of at least one CTC per 10 ml was
considered a positive result according to the re-
ported analytic detection limit of our assay [10].
Data are expressed as means or numbers (%).
Two-tailed p < 0.05 values were considered statisti-
cally significant. Fisher test was calculated to assess
the association between clinicopathological variables
and the CTC status.
Results
Exosomal miRNA levels associated with LBC and MBC
stages
After fully characterizing exosomes derived from cell
lines (Additional file 1: Figure S1), we firstly com-
pared the EmiR panel (21, 222, 221, 105, and 155)
between 53 BC patients and 8 healthy donors to in-
vestigate the diagnostic role of these EmiRs and, sec-
ondly, between different disease stages: LBC and
MBC to detect their prognostic implications.
EmiR expression levels were statistically different be-
tween groups (healthy donors and LBC and MBC pa-
tients). Both EmiR-21 (p = 0.017) and EmiR-105 (p =
0.009) showed statistically significant differences between
the three groups (Kruskal-Wallis test). Higher expression
levels of EmiR-21 and EmiR-105 (p = 0.013 and p = 0.029
respectively) were found in MBC patients compared to
healthy donors (Wilcoxon test). Furthermore, compari-
sons between LBC and MBC were found significantly dif-
ferent for EmiR-21 (p = 0.027) but not for EmiR-105 (p =
0.71). Emir-21 diagnostic potential of MBC was compared
with the current clinical biomarkers carbohydrate antigen
19.9 and carcinoembryonic antigen by logistic binary re-
gression. The Emir-21 was an independent diagnostic bio-
marker with a HR = 1.404 (95% CI = 1.028–1.918); (p =
0.033) (Additional file 1: Table S1) and the area under the
curve (AUC) of the ROC curve was 0.777 (95% CI =
0.566–0.987) (p = 0.029) (Additional file 1: Figure S2).
However, none of the clinical biomarkers could signifi-
cantly identify MBC patients (Additional file 1: Table S1).
Finally, EmiR-105 (p = 0.002), but not EmiR-21 (p = 0.09),
was able to discriminate between healthy donors and LBC
patients (Fig. 1a, b).
Exosomal miRNAs and clinical characteristics in LBC
patients under neoadjuvant chemotherapy
The association between expression levels of the EmiR
panel at Ext1 and Ext2 and the clinical and pathological
features are respectively summarized in Tables 1 and 2.
At Ext1, 20 of 47 patients (42.55%) with larger tumors
(III–IV) showed significantly higher EmiR-21 levels (p =
0.039) than those with smaller tumors.
According to hormone receptor expression at time of
diagnosis, PGR-negative patients (17 of 47, 36.2%)
showed a positive association with EmiR-222 expres-
sion (p = 0.017) at Ext1. Furthermore, 37 of 45 patients
(82%) showed association between EmiR-222 at Ext1
and the proliferation marker Ki-67 (p = 0.050), that it
was significantly associated with lower EmiR-21 levels
at Ext2 (p = 0.030). With respect to HER2, an inverse
significant association was found for EmiR-21 at Ext2
(p = 0.031) but not at Ext1 (p = 0.466). At the Ext2, we
found lower levels of EmiR-221 Ext2 in lymph
node-affected patients (p = 0.006).
BC subtypes and EmiR profile
We correlated our five EmiR panel with the four major dis-
tinct molecular BC subtypes, according to Perou’s classifi-
cation (Table 1) to address the clinical and relevant need of
identifying subgroups. At Ext1, EmiR-222 was significantly
associated with the different patient subgroups (p = 0.037):
it was under-expressed in luminal A tumors vs. basal-like
tumors (p = 0.004) and under-expressed in luminal A vs. lu-
minal B (p = 0.015). However, non-significant differences
were found between basal-like and luminal A/B, basal-like
and HER2, or luminal A/B and HER2 (Fig. 1c).
Predictive role of EmiRs
We analyzed the association of the EmiR panel at Ext2
with clinical response evaluated 3months after treat-
ment initiation. EmiR-21 did not show significant differ-
ences among partial response (PR), stable disease (SD),
and complete response (CR) groups (p = 0.062) and nei-
ther when comparing CR patients vs. those with worse
response to therapy (PR + SD) (p = 0.060) (Fig. 1d).
Association between EmiR expression and CTC presence
in LBC
We identified CTCs in 17 of 47 LBC patients (36.17%)
at Ext1. Mean number of CTCs present was 1.23 cells
per 10 ml of blood (range 0–10). At Ext2, CTCs were
identified in 19 of 47 (40.43%) LBC patients, with a
mean value of 1.60 cells per 10 ml (range 0–11). No sig-
nificant differences were found between the presence of
CTCs at Ext1 vs. Ext2 (p = 0.301 and p = 0.392 respect-
ively). Correlation between CTC status and the clinical
and pathological characteristics is shown in Add-
itional file 1: Table S2.
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Moreover, EmiR-21, EmiR-222, and EmiR-155 showed a
positive correlation with the presence and/or number of
CTCs in LBC patients. In fact, higher levels of EmiR-21 at
Ext2 were associated with the presence of CTCs at Ext1
(p = 0.032) (Fig. 2a). Besides, according to the number of
CTCs, we observed higher EmiR-21 levels at Ext2 in those
patients with higher number of CTCs at Ext1 (p = 0.045)
and Ext2 (p = 0.048) (Fig. 2b, c). Furthermore, we observed
a similar association between CTCs and EmiR-155 levels
at Ext2. EmiR-155 was significantly overexpressed in the
group of patients with ≥ 3 CTCs/10ml at Ext1 (p = 0.039)
(Fig. 2d). Finally, an association was found between higher
levels of EmiR-222 and higher number of CTCs at Ext2
(p = 0.019) but not at Ext1 (Fig. 2f, e).
Discussion
In the present study, we analyzed the role of five dif-
ferent exosomal miRNAs as a clinical tool to under-
stand diagnostic, prognostic, and treatment response
assessment.
Interestingly, one of the most important results ob-
served in our study was the correlation between EmiR
expression and disease stage. This way, EmiR-21 expres-
sion levels can distinguish localized from distant dis-
eased patients. We also found differences in EmiR-105
levels between localized BC and healthy donors. These
results might have important clinical implications for
the correct identification of the disease and subsequent
finest treatment choice. This could be particularly im-
portant in BC patients undergoing neoadjuvant chemo-
therapy, as it involves an advanced non-metastatic stage
and includes a variety of clinical scenarios. A significa-
tive proportion of patients under neoadjuvant chemo-
therapy will end up developing metastatic disease,
despite the administrated treatment. In addition, a per-
centage of them present distal disease at the time of
diagnosis, which the current clinical methods are unable
to detect. In consequence, these patients could be mis-
diagnosed and hence not appropriately treated. There-
fore, the ability of LB to differentiate among localized
Fig. 1 EmiR expression is associated with clinical stage, cancer subtype, and clinical response to neoadjuvant treatment. Expression of EmiR-21 (a)
and EmiR-105 (b) compared between healthy donors (HD), non-metastatic (LBC), and metastatic (MBC) breast cancer patients. EmiR-222 (c)
expression according to Perou’s classification in the LBC cohort, divided into four groups: basal-like (BL), luminal A (LA), luminal B (LB), and HER2.
EmiR-21 (d) expression at Ext2 in patients with complete response (CR), partial response (PR), or stable disease (SD). Data are presented as a box
and whiskers plot (min to max). *p > 0.05 and **p < 0.01. No significant comparisons are not represented
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disease, occult systemic disease, or not and healthy do-
nors should be noted. A potential application would lay
on the context of BC diagnostic, as despite the generally
satisfactory results from mammograms, they have some
important limitations, which can involve false negatives
(i.e., greater proportion of cancers are detected after a
negative mammogram). In fact, younger women (40–49
years) have lower mammographic sensitivity than older
ones (≥ 50 years). We suggest that these limitations
might be addressed by incorporating EmiR-21 and
EmiR-105 analysis, in addition to mammogram tests. In
this way, the LB could identify patients with metastatic
disease, even those patients who are misdiagnosed as
non-metastatic by the current clinical methods.
To assess the diagnostic ability of these EmiRs, we ana-
lyzed the correlation between EmiR levels in serum and dif-
ferent clinicopathological characteristics. miRNA-21 has
been shown to be overexpressed in numerous types of
tumor tissues [26], to be involved in cancer at almost all
stages [27], and to be associated with proliferation and
therefore growth. In the present study, serum EmiR-21 ex-
pression levels were positively correlated with tumor size,
indicating that patients with higher serum EmiR-21 levels
have larger tumors. Interestingly, we found lower levels of
EmiR-221 during neoadjuvant treatment, in those patients
with lymph node affection (N1-N3). The expression of
miR-221 has been identified as a good prognostic bio-
marker in breast cancer tissues, and it is associated with ER
positivity and lymph node negativity [28]. However, the
miR-221 is associated with tamoxifen resistance in breast
cancer cells [29]. In addition, Miller et al. [30] reported that
miR-221/222 expressions were upregulated in endocrine
therapy-resistant luminal-type breast cancer cells, which
could explain our results. The association between EmiR
expression levels, tumor size, and lymph node status sug-
gests their potential beneficial use as diagnostic biomarkers
to improve the stratification of metastasis risk in LBC.
We also observed lower levels of EmiR-21 in
HER2-positive patients during neoadjuvant treatment
with Trastuzumab (Ext2). Since EmiR-21 levels were not
different between HER2-positive and HER2-negative pa-
tients at diagnosis time (Ext1), our results are in accord-
ance with conclusions from similar studies [31, 32]
suggesting that this low expression of EmiR-21 might be
caused by the MAPK (ERK1/2) pathway blockage
through HER2/neu. These data highlight the prognostic
value of EmiR-21 to predict the treatment response of
these patients to Trastuzumab.
Table 1 Association between EmiR expression at Ext1 and clinicopathological characteristics in LBC patients
Ext1
EmiR-21 EmiR-222 EmiR-221 EmiR-105 EmiR-155
n Median p value Median p value Median p value Median p value Median p value
Age (years) < 50 27 1.518 0.983 1.506 0.966 1.161 0.667 11.199 0.897 1.901 0.302
≥ 50 20 1.671 1.592 1.375 8.362 3.247
Menopause Pre 30 1.579 0.330 1.585 0.658 1.399 0.232 9.474 0.947 1.904 0.250
Post 17 1.424 1.424 1.088 8.597 3.370
T T1–T2 27 1.265 0.039* 1.506 0.813 1.173 0.780 3.851 0.067 1.906 0.093
T3–T4 20 1.787 1.556 1.379 22.184 4.073
N 0 20 1.443 1.000 1.315 0.342 1.197 0.733 8.362 0.846 2.436 0.770
1–3 23 1.543 1.584 1.088 30.239 3.019
Estrogen receptor Negative 13 1.615 0.812 2.992 0.161 1.221 0.812 49.757 0.140 2.776 0.981
Positive 34 1.462 1.417 1.155 7.072 2.892
Progesterone receptor Negative 17 1.615 0.773 2.992 0.018* 1.597 0.465 49.757 0.116 2.776 0.947
Positive 30 1.403 1.271 1.064 7.072 2.778
HER2 Negative 36 1.531 0.466 1.465 0.880 1.149 0.563 8.362 0.744 3.117 0.421
Positive 11 1.265 2.019 1.596 14.130 1.055
KI67 < 20% 8 1.157 0.458 0.850 0.050 1.279 0.573 3.380 0.103 2.219 0.373
≥ 20 37 1.518 1.584 1.161 14.130 3.019
Perou’s classification Basal-like 8 1.566 0.976 3.179 0.037* 1.191 0.986 39.998 0.306 4.127 0.495
Luminal A 7 1.543 0.803 1.656 3.389 1.901
Luminal B 27 1.424 1.513 1.139 7.750 3.215
HER2neu 5 1.960 2.094 1.597 60.097 1.055
Wilcoxon signed-rank test and Kruskal-Wallis test were used. Abbreviations: CTCs circulating tumor cells, Ext1 basal extraction, Ext2 extraction during neoadjuvant
treatment, T tumor size, N lymph node status. *p > 0.05
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Additionally, an inverse association was detected be-
tween EmiR-21 and Ki67 at Ext2. This correlation might
predict the biological behavior of BC and its treatment
response. Similar conclusions can be found in additional
studies where the correlation among Ki67, HER2, and
treatment was analyzed [33].
A correct BC diagnosis necessarily involves the iden-
tification of the different BC subtypes, what is crucial
not only for risk stratification, but also for selecting the
most appropriate patient treatment. Currently, identifi-
cation of these BC subtypes depends on traditional
pathological assessments with a limited number of bio-
markers to define each subtype due to the technical im-
possibility of molecular profiling each tissue. However,
despite the clinical relevance of these histopathological
methods, the information provided is limited, with defi-
cient genetic characterization of each patient and tis-
sue. We observed associations between specific EmiRs
and different BC subtypes. Our results, in agreement
with the study of Sung EH et al. [34] in which miRNAs
related to different BC subtypes and their target genes
were identified, suggest that EmiRs could act as
putative biomarkers valuable to improve classification
and diagnosis of different BC subtypes. Therefore,
identification of additional EmiRs will help to improve
the genetic characterization of these tumor subtypes.
Hence, we suggest that EmiRs, on further validation
studies, as liquid biopsy biomarkers might become a
non-invasive supplementary tool to the current BC
classification methods. The use of these liquid bio-
markers involves the possibility to obtain genetic infor-
mation about the status of the disease on different
temporal points, since BC is a dynamic disease that
changes in the space and over time. These biological
dynamics might be responsible for future relapses and
resistance to treatment [35]. Therefore, the detection of
changes in EmiRNA levels in biological fluids over
time, might provide this information. Despite it was not
the objective of our work, the EmiRNAs could be used
to detect relapses in early stages and to detect early re-
sistance to treatment.
Finally, we found a positive association between the
presence of CTCs at baseline status and higher levels
of EmiR-21, EmiR-155, and EmiR-222. As these miR-
NAs have been associated with tumor aggressiveness,
promoting the proliferation and migration of tumor
cells [22–24], higher levels of these EmiRs could ex-
plain more CTC dissemination.
Table 2 Association between EmiR expression at Ext2 and clinicopathological characteristics in LBC patients
Ext2
EmiR-21 EmiR-222 EmiR-221 EmiR-105 EmiR-155
n Median p value Median p value Median p value Median p value Median p value
Age (years) < 50 19 3.975 0.585 1.851 0.536 1.705 0.771 2.534 0.166 2.173 0.536
≥ 50 14 3.033 2.100 1.718 11.182 1.401
Menopause Pre 20 4.159 0.094 2.250 0.461 1.890 0.338 3.916 0.224 2.177 0.768
Post 13 2.192 1.551 1.422 10.603 1.507
T T1–T2 18 3.668 0.233 2.382 0.828 2.238 0.219 16.929 0.112 2.601 0.159
T3–T4 15 3.246 1.851 1.286 3.484 1.819
N 0 11 3.975 0.621 3.037 0.621 2.490 0.006* 21.588 0.445 1.344 0.928
1–3 18 3.477 2.250 1.095 8.885 2.177
Estrogen receptor Negative 8 2.133 0.450 1.213 0.475 1.095 0.585 5.405 0.529 0.839 0.120
Positive 25 3.933 2.649 2.000 11.760 2.173
Progesterone receptor Negative 11 2.192 0.541 1.338 0.760 1.787 0.541 7.327 0.789 3.224 0.849
Positive 22 3.668 2.250 1.686 8.528 1.899
HER2 Negative 27 3.933 0.031* 3.037 0.056 1.705 0.744 5.297 0.484 2.173 0.161
Positive 6 0.857 0.536 41.874 46.810 0.639
KI67 < 20% 6 4.996 0.427 1.464 0.283 0.321 0.176 3.691 0.963 1.355 0.191
≥ 20 27 3.246 3.037 1.787 10.444 3.201
Perou’s classification Basal-like 5 2.192 0.655 1.338 0.666 1.286 0.666 3.484 0.510 0.983 0.232
Luminal A 5 6.058 0.729 0.334 2.085 1.367
Luminal B 20 3.324 3.052 2.038 16.580 3.459
HER2neu 3 2.074 0.175 0.307 10.603 0.695
Wilcoxon signed-rank test and Kruskal-Wallis test were used. Abbreviations: CTCs circulating tumor cells, Ext2 extraction during neoadjuvant treatment, T tumor
size, N lymph node status. *p > 0.05
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Conclusion
Currently used techniques are not sufficiently sensi-
tive or specific so as to ensure a correct diagnosis of
metastatic disease in breast cancer and certainly are
unsatisfactory for therapeutic guidance. New ap-
proaches are needed to address this problem, requir-
ing further research that involves novel markers and
technologies to discover and validate improved bio-
markers such as EmiRs. In this way, liquid biopsy
based on serum EmiRs can become an additional
clinical tool for improving BC diagnosis.
Limitations of the study and interpretation
We would like to remark that our study included a sin-
gle hospital with a limited cohort of patients; therefore,
our results need further validation with a larger patient
population. Inclusion of more patients, but also healthy
donors, would improve the statistical power of our re-
sults. According with these limitations and as a result of
the data of the EmiRNA profile established in this work,
we are validating these results in different Spanish hos-
pitals, using as central laboratory, the GENyO center.
On the other hand, the clinical utility of EmiRs should
include reproducibility and analytic validity. These re-
quirements involve the establishment of standard
operating protocols (SOP) through multicenter clinical
trials. These SOP not only should include the molecular
analyses, but also include how the sample is collected,
stored, and transported until the final molecular ana-
lyses. For LB to become a clinical reality instead of a
simple proposal, the establishment and approval of these
SOP by different laboratories and the performance of
multicenter clinical trials is needed.
Additional files
Additional file 1: Figure S1. Exosome characterization by TEM and
Western blot. TEM images of exosomes derived from BC cell lines
demonstrated that our methodology was successful in isolating exosomes,
observing double-membrane vesicles with a diameter of ~ 150 nm (A). Fur-
thermore, Western blot characterization showed positive expression of
Hsp70 and CD9 exosomal proteins in these exosomes but negative expres-
sion of GM-130, which was present in the MCF-7 lysate positive control (B).
Figure S2. ROC Curve of MBC identification by EmiR-21 (Ext1). Gray line rep-
resents EmiR-21 (Ext1) values for sensibility and specificity while black dotted
line represents random predictor baseline. Light gray area represents EmiR-
21 (Ext1) area under the curve (AUC) = 0.777. Table S1. Univariate logistic
binary regression for MBC identification. Abbreviations: CA19.9, Carbohy-
drate Antigen 19.9; CEA, Carcinoembryonic Antigen; Ext1, basal extraction;
HR, Hazard Ratio. Table S2. Association between CTC presence and clinico-
pathological features. Abbreviations: CTCs, circulating tumor cells; Ext1, basal
extraction; Ext2, extraction during neoadjuvant treatment; T, tumor size; N,
lymph node status. (ZIP 352 kb)
Fig. 2 CTC detection correlates with EmiR expression. Comparison of EmiR-21 expression at Ext2 in patients with the presence or absence of
CTCs at Ext1 (a), and correlation with the number of CTCs at Ext1 (b) and Ext2 (c). EmiR-155 expression comparison between patients with three
or more CTCs per sample and less than three CTCs (d). Correlation of EmiR-222 expression and number of CTCs at Ext1 (e) and Ext2 (F). *p > 0.05
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Abbreviations
AUC: Area under the curve; BC: Breast cancer; cfNAs: Cell-free nucleic acids;
CR: Complete response; CTCs: Circulating tumor cells; EmiRs: Exosomal
microRNAs; ER: Estrogen receptor; Ext1: Diagnosis time; Ext2: After 4 cycles of
doxorubicin/cyclophosphamide; LB: Liquid biopsy; LBC: Localized breast
cancer; MBC: Metastatic breast cancer; N: Lymph node status;
PGR: Progesterone receptor; PR: Partial response; ROC: Receiver-operating
characteristics; SD: Stable disease; SOP: Standard operating protocols;
T: Tumor size
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